ChemoCentryx, Inc. - Product Pipeline Review - 2012

Global Markets Direct, June 2012, Pages: 55

ChemoCentryx, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “ChemoCentryx, Inc. - Product Pipeline Review - 2012” provides data on the ChemoCentryx, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ChemoCentryx, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ChemoCentryx, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ChemoCentryx, Inc. - Brief ChemoCentryx, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ChemoCentryx, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ChemoCentryx, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ChemoCentryx, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ChemoCentryx, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ChemoCentryx, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ChemoCentryx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ChemoCentryx, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ChemoCentryx, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of ChemoCentryx, Inc.; ChemoCentryx, Inc. - Key Therapeutics; ChemoCentryx, Inc. - Pipeline Overview and Promising Molecules; ChemoCentryx, Inc. - News; ChemoCentryx, Inc. - Latest Updates; ChemoCentryx, Inc. - Pipeline; ChemoCentryx, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
ChemoCentryx, Inc. Snapshot
ChemoCentryx, Inc. Overview
Key Information
Key Facts
ChemoCentryx, Inc. – Research and Development Overview
Key Therapeutic Areas
ChemoCentryx, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ChemoCentryx, Inc. – Pipeline Products Glance
ChemoCentryx, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
ChemoCentryx, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ChemoCentryx, Inc. – Drug Profiles
CCX140
Product Description
Mechanism of Action
R&D Progress
CCX168
Product Description
Mechanism of Action
R&D Progress
CCX662
Product Description
Mechanism of Action
R&D Progress
GSK1605786
Product Description
Mechanism of Action
R&D Progress
Oncology program
Product Description
Mechanism of Action
R&D Progress
ChemoCentryx, Inc. – Pipeline Analysis
ChemoCentryx, Inc. – Pipeline Products by Therapeutic Class
ChemoCentryx, Inc. – Pipeline Products By Target
ChemoCentryx, Inc. – Pipeline Products by Route of Administration
ChemoCentryx, Inc. – Pipeline Products By Mechanism of Action
ChemoCentryx, Inc. – Recent Pipeline Updates
ChemoCentryx, Inc. - Dormant Projects
ChemoCentryx, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CCX832
ChemoCentryx, Inc. – Locations And Subsidiaries
Head Office
ChemoCentryx, Inc., Recent Developments
ChemoCentryx, Inc.- Press Release
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress
May 05, 2009: ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
Financial Deals Landscape
ChemoCentryx, Inc., Deals Summary
ChemoCentryx, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
ChemoCentryx Raises $50 Million In Venture Financing
ChemoCentryx Secures $30 Million In Series D Round Of Financing
ChemoCentryx Secures $17.7 Million In Series C Financing
ChemoCentryx Secures $33 Million In Financing
Partnerships
GlaxoSmithKline Enters Into Co-Development Agreement With ChemoCentryx
Forest Labs Enters Into An Agreement With ChemoCentryx
Licensing Agreements
GlaxoSmithKline Exercises Option For Licensing Agreement With ChemoCentryx For CCX354
GlaxoSmithKline Enters Into Licensing Agreement With ChemoCentryx
Equity Offering
ChemoCentryx Completes IPO Of Common Stock For $45 Million
ChemoCentryx Announces Private Placement For $7 Million
ChemoCentryx Announces Private Placement For $5 Million
Debt Offering
ChemoCentryx Completes Private Placement Of 5% Convertible Note For $9 million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
ChemoCentryx, Inc., Key Information
ChemoCentryx, Inc., Key Facts
ChemoCentryx, Inc. – Pipeline by Indication, 2012
ChemoCentryx, Inc. – Pipeline by Stage of Development, 2012
ChemoCentryx, Inc. – Monotherapy Products in Pipeline, 2012
ChemoCentryx, Inc. – Phase II, 2012
ChemoCentryx, Inc. – Pre-Clinical, 2012
ChemoCentryx, Inc. – Pipeline By Therapeutic Class, 2012
ChemoCentryx, Inc. - Pipeline By Target, 2012
ChemoCentryx, Inc. – Pipeline By Route of Administration, 2012
ChemoCentryx, Inc. – Pipeline Products By Mechanism of Action, 2012
ChemoCentryx, Inc. – Recent Pipeline Updates, 2012
ChemoCentryx, Inc. - Dormant Developmental Projects,2012
ChemoCentryx, Inc. - Discontinued Pipeline Products, 2012
ChemoCentryx, Inc., Deals Summary
ChemoCentryx Raises $50 Million In Venture Financing
ChemoCentryx Secures $30 Million In Series D Round Of Financing
ChemoCentryx Secures $17.7 Million In Series C Financing
ChemoCentryx Secures $33 Million In Financing
GlaxoSmithKline Enters Into Co-Development Agreement With ChemoCentryx
Forest Labs Enters Into An Agreement With ChemoCentryx
GlaxoSmithKline Exercises Option For Licensing Agreement With ChemoCentryx For CCX354
GlaxoSmithKline Enters Into Licensing Agreement With ChemoCentryx
ChemoCentryx Completes IPO Of Common Stock For $45 Million
ChemoCentryx Announces Private Placement For $7 Million
ChemoCentryx Announces Private Placement For $5 Million
ChemoCentryx Completes Private Placement Of 5% Convertible Note For $9 million

List of Figures
ChemoCentryx, Inc. – Pipeline by Indication, 2012
ChemoCentryx, Inc. – Pipeline by Stage of Development, 2012
ChemoCentryx, Inc. – Monotherapy Products in Pipeline, 2012
ChemoCentryx, Inc. – Pipeline By Therapeutic Class, 2012
ChemoCentryx, Inc. - Pipeline By Target, 2012
ChemoCentryx, Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Ixia - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Dell Inc.
• SunGard - Profile - US
• CIBER Inc
• Amazon - Point of Realization in 2013?